JNJ 67544412
Alternative Names: JNJ-4412; JNJ-67544412Latest Information Update: 28 Aug 2024
Price :
$50 *
At a glance
- Originator Janssen Research & Development
- Class Antineoplastics; Cyclic hydrocarbons; Nucleotides
- Mechanism of Action STING1 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for preclinical development in Solid-tumours in USA (Intratumoural)
- 27 Jul 2020 Preclinical trials in Solid tumours in USA (Intratumoural) before June 2020
- 22 Jun 2020 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 111th Annual Meeting of the American Association for Cancer Research - II